DMH1: Selective BMP Type I Receptor Inhibitor for Cancer and Organoid Research

Executive Summary: DMH1 is a dorsomorphin analog that selectively inhibits BMP type I receptors, especially ALK2, with an IC₅₀ of 107.9 nM and negligible off-target effects on VEGF signaling or related kinases (APExBIO product page). DMH1 robustly blocks Smad1/5/8 phosphorylation and downregulates Id gene expression in non-small cell lung cancer (NSCLC) models, suppressing migration, invasion, and proliferation, while inducing cell death (Yang et al., 2025). In A549 xenograft mouse models, DMH1 reduces tumor volume by ~50% and extends doubling time. Its high selectivity and solubility in DMSO (≥9.51 mg/mL) make it ideal for research applications in BMP signaling and organoid engineering. APExBIO supplies DMH1 as either a 10 mM DMSO solution or solid powder for research use only.

Biological Rationale

The bone morphogenetic protein (BMP) pathway orchestrates key processes in tissue development, stem cell fate, and cancer progression. BMP type I receptors, such as ALK2 and ALK3, mediate Smad1/5/8 activation, regulating genes like Id1, Id2, and Id3 (Yang et al., 2025). Aberrant BMP signaling is linked to tumorigenesis, particularly in NSCLC, where excessive pathway activation enhances cell migration, invasion, and proliferation. In stem cell-derived organoid systems, precise BMP modulation is critical for balancing self-renewal and differentiation, as shown by the inability of conventional cultures to recapitulate in vivo cellular diversity without targeted pathway manipulation (Yang et al., 2025).

Mechanism of Action of DMH1

DMH1 is a small-molecule inhibitor structurally related to dorsomorphin but with enhanced selectivity for BMP type I receptors. It binds to and inhibits ALK2 with an IC₅₀ of 107.9 nM and ALK3 with submicromolar potency (<0.5 μM). DMH1 does not inhibit VEGF signaling, nor does it affect kinases such as KDR, ALK5, AMPK, or PDGFRβ under standard in vitro conditions (APExBIO). In cell-based assays, DMH1 blocks BMP-mediated phosphorylation of Smad1/5/8, suppressing downstream Id gene transcription. It does not interfere with p38/MAP kinase signaling or Activin A-induced Smad2 activation, confirming signaling specificity. This precision enables researchers to dissect BMP-driven effects on cell fate and tumor biology while minimizing off-target artifacts (Related article—this review extends mechanistic insights by providing quantitative in vivo benchmarks).

Evidence & Benchmarks

• DMH1 inhibits ALK2 kinase activity with an IC₅₀ of 107.9 nM; ALK3 is also inhibited with IC₅₀ <0.5 μM (APExBIO product page).
• Does not inhibit VEGF signaling, KDR, ALK5, AMPK, or PDGFRβ at concentrations effective for BMP inhibition (APExBIO).
• Reduces phosphorylation of Smad1/5/8 in NSCLC cell lines; suppresses Id1, Id2, and Id3 gene expression (Yang et al., 2025, Fig. 4B-D).
• Inhibits NSCLC cell migration, invasion, and proliferation; induces apoptosis in vitro (Yang et al., 2025, Supp. Data 3).
• In A549 xenograft mouse studies, DMH1 extends tumor doubling time and reduces tumor volume by ~50% at 10 mg/kg dosing (Yang et al., 2025, Fig. 5A-F).
• Soluble in DMSO (≥9.51 mg/mL); insoluble in water and ethanol; optimal handling at 37°C with ultrasonic shaking (APExBIO).
• Facilitates controlled shifts in organoid self-renewal and differentiation when combined with other pathway modulators (Yang et al., 2025).

Applications, Limits & Misconceptions

DMH1's main applications are in NSCLC research, organoid engineering, and dissecting BMP-dependent processes. Its precise inhibition of ALK2/ALK3 makes it a valuable tool for:

• Modeling and suppressing BMP-driven tumor progression in NSCLC and other solid tumors.
• Fine-tuning stem cell fate and differentiation in complex organoid systems, as shown by increased cell diversity upon BMP pathway modulation (Yang et al., 2025).
• High-throughput screens requiring minimal off-target kinase inhibition.

For a comprehensive look at DMH1’s role in dynamic tuning of self-renewal and differentiation, see this review—the present article provides updated in vivo and workflow integration data not covered in the prior analysis. For broader context on DMH1’s position among selective BMP inhibitors in advanced organoid and cancer studies, see this detailed comparison; here, we focus on practical solubility and selectivity parameters for reproducible results.

Common Pitfalls or Misconceptions

• DMH1 is not suitable for inhibiting non-BMP kinases such as ALK5, AMPK, or VEGFR2 (KDR); it shows negligible activity against these targets at effective concentrations for BMP inhibition (APExBIO).
• It is insoluble in water or ethanol; attempts to dissolve DMH1 in these solvents will result in precipitation and loss of activity.
• Long-term storage of DMH1 solutions is not recommended; only short-term use is advised due to DMSO oxidation risk and compound stability.
• Not intended for clinical or in vivo human use; strictly for research applications.
• Does not induce differentiation or affect p38/MAP kinase or Activin A-induced Smad2 signaling—specific to BMP pathways.

Workflow Integration & Parameters

DMH1 (SKU: B3686, by APExBIO) is supplied as a solid or 10 mM DMSO solution (product page). For optimal solubility, dissolve powder in DMSO (≥9.51 mg/mL), warming to 37°C and employing ultrasonic shaking as needed. Stock solutions should be stored at -20°C and used within one week for maximum stability. DMH1 is insoluble in water and ethanol; DMSO is required for all in vitro and in vivo applications.

Typical cellular assays employ DMH1 at 0.1–5 μM, depending on cell type and endpoint. In murine xenograft models, dosing at 10 mg/kg daily (intraperitoneal) recapitulates published antitumor effects. For organoid applications, DMH1 is used singly or combined with Wnt/Notch modulators to tune self-renewal and differentiation (Yang et al., 2025). For a protocol on integrating DMH1 into high-throughput stem cell fate screens, see this resource; the current article adds quantitative benchmarks for NSCLC and solubility guidance.

Conclusion & Outlook

DMH1 is a validated, highly selective BMP type I receptor inhibitor with proven utility in dissecting BMP signaling in cancer and organoid research. Its specificity, solubility, and reproducible performance in NSCLC and advanced organoid models position it as a reference compound for both mechanistic studies and workflow development. Ongoing research is expanding DMH1’s use in high-throughput and combinatorial applications, as well as in translational models of tissue regeneration and tumor suppression (Yang et al., 2025). For ordering and detailed protocols, consult the APExBIO DMH1 product page.